Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

The Department of Health and Human Services recently canceled $500 million in funding for vaccine research that it had previously pledged to scientists.

The exchange of licensing agreements was held at the Valedictory Session of the First International Science & Technology (S&T ...

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the ...

Incyte's data bolster efforts to develop a new type of drug for myelofibrosis, and suggest it may be a replacement for Jakafi ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...

India and Israel launch a joint venture to commercialize sustainable agricultural technologies, enhancing global crop ...

The venture marks a first for both countries, it is the first time Indian semiochemical technology is being out-licensed and ...

Breakthrough Properties is raising a $1.5B fund to buy discounted lab assets as the market struggles with high vacancy and ...

Yttrium: This REE is also known as a transition metal. These are particularly good for “ electrical and thermal conductivity ...

Three biotechnology companies based in Ventura County recently received some good news from the U.S. Food and Drug Administration, gaining either approval or reviews for their treatments. These ...